These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 33250512)
1. Treatment strategies for breast cancer brain metastases. Bailleux C; Eberst L; Bachelot T Br J Cancer; 2021 Jan; 124(1):142-155. PubMed ID: 33250512 [TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Brain Metastasis: A Comprehensive Review. Raghavendra AS; Ibrahim NK JCO Oncol Pract; 2024 Oct; 20(10):1348-1359. PubMed ID: 38748968 [TBL] [Abstract][Full Text] [Related]
3. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Shah N; Mohammad AS; Saralkar P; Sprowls SA; Vickers SD; John D; Tallman RM; Lucke-Wold BP; Jarrell KE; Pinti M; Nolan RL; Lockman PR Pharmacol Res; 2018 Jun; 132():47-68. PubMed ID: 29604436 [TBL] [Abstract][Full Text] [Related]
4. New insights and emerging therapies for breast cancer brain metastases. Lim E; Lin NU Oncology (Williston Park); 2012 Jul; 26(7):652-9, 663. PubMed ID: 22888567 [TBL] [Abstract][Full Text] [Related]
5. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies. Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445 [TBL] [Abstract][Full Text] [Related]
6. A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience. McKee MJ; Keith K; Deal AM; Garrett AL; Wheless AA; Green RL; Benbow JM; Dees EC; Carey LA; Ewend MG; Anders CK; Zagar TM Oncologist; 2016 Jan; 21(1):16-20. PubMed ID: 26659221 [TBL] [Abstract][Full Text] [Related]
7. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395 [TBL] [Abstract][Full Text] [Related]
8. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140 [TBL] [Abstract][Full Text] [Related]
9. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405 [TBL] [Abstract][Full Text] [Related]
10. Optimal management of brain metastases from breast cancer. Issues and considerations. Bartsch R; Berghoff AS; Preusser M CNS Drugs; 2013 Feb; 27(2):121-34. PubMed ID: 23239265 [TBL] [Abstract][Full Text] [Related]
11. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer. Yomo S; Hayashi M; Cho N J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546 [TBL] [Abstract][Full Text] [Related]
12. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study. Shawky H; Tawfik H J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer brain metastases: Molecular subtype, treatment and survival. Crozier JA; Cornell LF; Rawal B; Perez EA Breast Dis; 2016; 36(4):133-141. PubMed ID: 27802190 [TBL] [Abstract][Full Text] [Related]
14. Management of Brain and Leptomeningeal Metastases from Breast Cancer. Pellerino A; Internò V; Mo F; Franchino F; Soffietti R; Rudà R Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198331 [TBL] [Abstract][Full Text] [Related]
15. Brain metastases in breast cancer. Sim HW; Morris PG; Patil S; Khasraw M Expert Rev Anticancer Ther; 2014 Feb; 14(2):173-83. PubMed ID: 24308683 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies. Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232 [TBL] [Abstract][Full Text] [Related]
17. microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy. Kanchan RK; Siddiqui JA; Mahapatra S; Batra SK; Nasser MW Mol Cancer; 2020 Feb; 19(1):29. PubMed ID: 32059676 [TBL] [Abstract][Full Text] [Related]
18. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598 [TBL] [Abstract][Full Text] [Related]
19. Current challenges in the management of breast cancer brain metastases. O'Sullivan CC; Davarpanah NN; Abraham J; Bates SE Semin Oncol; 2017 Apr; 44(2):85-100. PubMed ID: 28923217 [TBL] [Abstract][Full Text] [Related]
20. Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease. Mills MN; King W; Soyano A; Pina Y; Czerniecki BJ; Forsyth PA; Soliman H; Han HS; Ahmed KA J Neurooncol; 2022 Apr; 157(2):249-269. PubMed ID: 35244835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]